Physician profile
Abdullah Arshad
NPI 1477660637
$11,061.76
in general payments reported to CMS, 2019-2025
52 companies · $1,796 in 2025
The $1,796 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,016 · 2020: $1,365 · 2021: $1,777 · 2022: $1,471 · 2023: $1,646 · 2024: $990 · 2025: $1,796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,470 · Travel and Lodging: $754 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,470.06 |
| Travel and Lodging | $754.39 |
| Education | $207.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,379.75 | 2019-2024 | Ozempic, Rybelsus |
| Sunovion Pharmaceuticals INC. | $1,091.75 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $987.62 | 2020-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $862.75 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $799.93 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Amgen INC. | $787.40 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $613.57 | 2021-2024 | Vraylar |
| Lilly USA, LLC | $472.09 | 2019-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $418.19 | 2019-2025 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $401.44 | 2019-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $308.44 | 2023-2025 | Gemtesa, Aptiom |
| Astellas Pharma US INC | $297.55 | 2020-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $293.86 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Lundbeck LLC | $261.07 | 2022-2025 | Rexulti |
| Allergan, INC. | $156.16 | 2020 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullah Arshad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.